EVOTEC EXPANDS beLAB1407 BRIDGE PARTNERSHIP WITH BRISTOL MYERS SQUIBB TO INCLUDE 3 NEW UNIVERSITY PARTNERS
Hamburg, Germany, 22 November 2023:
- beLAB1407 WAS CREATED BY EVOTEC AND BRISTOL MYERS SQUIBB TO TRANSLATE INNOVATIONS FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
- EVOTEC’S UNIQUE MULTIMODALITY PLATFORM WILL NOW BE MADE AVAILABLE TO THE UNIVERSITY OF BRISTOL, UNIVERSITY OF GLASGOW AND QUEEN MARY UNIVERSITY OF LONDON TO VALIDATE FIRST-IN-CLASS CONCEPTS
Evotec SE today announced the expansion of its $20 million beLAB1407 BRIDGE partnership with Bristol Myers Squibb to include the Universities of Bristol and Glasgow as well as Queen Mary University of London.
beLAB1407 was launched in 2021 with the Universities of Birmingham, Dundee, Edinburgh and Nottingham as founding partners to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas. Under the expanded beLAB1407 agreement, the Universities of Bristol and Glasgow as well as Queen Mary University of London will benefit from access to funding, expertise and drug discovery and development platforms spanning multiple disease areas and modalities.